IMPAACT Studies in Development

The study you are looking for is in protocol development.

As the study protocol reaches Version 1.0, a study page will be developed.

  Study Number
(DAIDS ID)
Study Title Status

IMPAACT 2013

(30074)

Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, RSV/NS2/N/delta M2-2-HindIII, Lot RSV#011A, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age

In Development

IMPAACT 2012

(30073)

Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID cp delta M2-2, Lot RSV#009A, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age

In Development

IMPAACT 2010

(30129)

Phase III Study of the Virologic Efficacy and Safety of Dolutegravir-Containing versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and their Infants

In Development

IMPAACT 2011

(30072)

Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID delta M2-2 1030s, Lot RSV#010A, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age

In Development

IMPAACT 2009

(30020)

Feasibility, Acceptability and Safety of Oral Pre-Exposure Prophylaxis for Primary HIV Prevention during Pregnancy and Breast Feeding in Adolescents and Young Women

In Development

IMPAACT 2003B

(12041)

(Phoenix) Protecting Households on Exposure to Newly Diagnosed Index Multidrug-Resistant TB Patients

In Development

IMPAACT 2008

(20735)

Phase I/II Multisite Randomized Controlled Study of Monoclonal Antibody VRC01 Combined with Antiretroviral Therapy to Promote Clearance of HIV-1 Infected Cells in Infants

In Development

IMPAACT 2006

(12069)

NextGen Strategy Trial: A Phase II, Randomized Study Assessing Lopinavir/Ritonavir- and Dolutegravir-Based Antiretroviral Treatment in Infants and Children >= 1 Month to < 3 Years of Age

In Development

IMPAACT 2005

(20721)

A Phase I/II Open-label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination with Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-infected and HIV-uninfected Children with MDR-TB

In Development

IMPAACT 2004

(12050)

Phase I/II, Randomized, Placebo-Controlled Study of the Safety and Immunogenicity of Clade C ALVAC-HIV (vCP2438) and Bivalent Subtype C gp120/MF59® in South African Breastfeeding Infants

In Development

IMPAACT 2002

(12051)

Combined Cognitive Behavioral Therapy and a Medication Management Algorithm for Treatment of Depression among Youth Living with HIV in the United States

In Development


Return to the full list of studies

 

Funded by the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health of the US National Institutes of Health, US Department of Health and Human Services.